Francois Brisebois, an analyst from LifeSci Capital, reiterated the Buy rating on COMPASS Pathways. The associated price target remains the same with $23.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Francois Brisebois has given his Buy rating due to a combination of factors tied to COMPASS Pathways’ lead asset COMP360 and its advancing regulatory path in treatment-resistant depression. He highlights that the rolling NDA submission is progressing as planned with completion targeted for 4Q26, and he notes that the upcoming 26-week data from the COMP006 trial in early 3Q26 should finalize the NDA package and further validate durability of effect.
Brisebois also points to the strong, consistent efficacy observed across pivotal Phase 3 studies, which he believes positions COMP360 well for commercial success and potential first-mover status among classic psychedelics in TRD. In parallel, he views the company’s ongoing commercial preparations, strategic partnerships to integrate COMP360 into existing interventional psychiatry infrastructure, and continued pipeline execution in PTSD as supporting his constructive outlook and justify maintaining an unchanged $23 price target.
In another report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $18.00 price target.